Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Recombinant coagulation factor VIII Fc fusion protein (FVIII (Fc fusion))
- Target
- FVIII (Fc fusion)
- Molecular classification
- Other (Recombinant blood coagulation factor therapeutic)
01
Overview
Efmoroctocog alfa (Eloctate) is a recombinant, B-domain-deleted coagulation factor VIII Fc fusion protein, produced using recombinant DNA technology. It is used as a therapeutic agent for control, prevention, and routine prophylaxis of bleeding episodes in adults and children with hemophilia A, a genetic disorder marked by deficient activity of endogenous factor VIII. Eloctate works by supplementing the missing factor VIII, allowing normal coagulation. It does not act on a receptor or regulatory pathway by binding; instead, its clinical efficacy derives from direct protein replacement.
- Other names
- Antihemophilic factor (recombinant), Fc fusion proteinEfmoroctocog alfaRecombinant Factor VIII Fc fusion protein
02
Mechanism of action
Replacement of deficient endogenous factor VIII to restore normal blood clotting
03
Biological functions
Blood clotting/coagulation
04
Disease associations
Hemophilia A
05
Safety considerations
Development of factor VIII inhibitors (antibodies that neutralize the therapeutic effect)Hypersensitivity, allergic reactionsCommon mild side effects: muscle/joint pain, tiredness, headache, rash
06
Biomarkers
Factor VIII activity levels in plasmaPresence of anti-factor VIII inhibitors (antibodies inhibiting efficacy)
Beyond the preview
Go deeper on Recombinant coagulation factor VIII Fc fusion protein (FVIII (Fc fusion)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinant coagulation factor VIII Fc fusion protein (FVIII (Fc fusion)).